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Abstract. Recent epidemiological observations have drawn attention to the rapid rise in the burden caused by Parkinson’s
disease over the past years, emphasizing that Parkinson’s disease is a matter of serious concern for our future generations.
A recent report by Public Health England corroborates this message, by providing new insight on trends in deaths associated
with neurological diseases in England between 2001 to 2014. The report indicates that mortality associated with Parkinson’s
disease and related disorders increased substantially between 2001 and 2014. This trend is partially explained by increased
longevity in the population. However, it is possible that changes in exposure to risk factors, recent improvements in multidis-
ciplinary care (leading to prolonged survival), and improved diagnostic awareness or improved registration also influenced
the observed trend. Furthermore, patients with Parkinson’s disease and related disorders were found to die at an advanced
age, and the majority die in a care home or hospital, despite a preponderant preference for many patients and their families
to spend their last days at home. To combat these concerning observations, future efforts should be focused on providing
resources for vulnerable elderly Parkinson patients, avoiding unplanned hospital admissions and out-of-home deaths as much
as possible. Possible solutions include a community-based network of specifically trained allied health therapists, personal
case managers for Parkinson patients, dedicated Parkinson nursing homes, and improved centralised support services from
university clinics to regional community hospitals aimed at facilitating optimal wide-scale care delivery.
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INTRODUCTION
At population level, the burden caused by Parkin-
son’s disease (PD) has recently increased, leading
some to label this as a Parkinson “pandemic” [1, 2].
∗Correspondence to: Bastiaan R. Bloem, MD, PhD, Depart-
ment of Neurology, Donders Institute for Brain, Cognition and
Behaviour, Radboud University Medical Center, PO Box 9101,
6500 HB Nijmegen, The Netherlands. E-mail: bas.bloem@rad
boudumc.nl.
Scrutiny of temporal trends in causes of death
can offer useful complementary information in this
regard. Here, we draw attention to a recently pub-
lished report by Public Health England on trends
in deaths associated with neurological diseases in
England between 2001 to 2014, [3] which contains
several interesting observations concerning Parkin-
son’s disease and related disorders (PDRD). (Box 1)
We will summarise these findings, and address some
implications for future healthcare needs. Specifically,
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Box 1. Key observations in the Public Health England report
1. Mortality associated with Parkinson’s disease
and related disorders (PDRD) increased
substantially between 2001 and 2014; this trend
appears to be partially explained by increased
longevity.
2. PDRD patients generally die at an advanced
age.
3. The majority of PDRD patients die in a care
home or hospital.
we focus on the frequency, age and place of deaths
associated with PDRD, as well as on temporal trends
in the frequency of these deaths.
CAUSES OF DEATH IN THE AGEING
POPULATION: THE PUBLIC HEALTH
ENGLAND REPORT
In the United Kingdom, it has long been a legal
requirement to report deaths to the Office of National
Statistics, yielding near-complete mortality data on a
population-wide scale (https://www.ons.gov.uk/peop
lepopulationandcommunity/birthsdeathsandmarriag
es/deaths). For each deceased individual, health-
care professionals register a single underlying
cause of death, as well as up to 15 contributory
conditions on the death certificate. Conditions
are coded in line with the International Statistical
Classification of Diseases and Related Health
Problems.
According to the Public Health England report,
[3] 6.590.453 individuals aged 20 years and over
died in England between 2001 and 2014. Of these
deaths, 366.728 (6%) were associated with at least
one neurological condition (listed as the underlying
cause or a contributory cause of death). The report
also contains data on deaths associated with seven
specific groups of neurological conditions: epilepsy;
motor neurone disease and spinal muscular atrophy;
multiple sclerosis and inflammatory disorders; neuro-
muscular diseases; traumatic brain and spine injury;
tumours of the nervous system; and PDRD. The
latter group comprised all disorders characterized
by parkinsonism (including atypical parkinsonisms),
other extrapyramidal disorders (including chorea), or
tic disorder. Of note, dementia (including demen-
tia with Lewy bodies) and stroke were not among
the groups of neurological conditions analysed in
the above-referenced report, however, they could be
recorded as the underlying cause of death on a death
certificate.
COMMON CAUSES OF DEATH
The group that was most commonly listed on death
certificates between 2001 and 2014 was PDRD; these
were mentioned on 31% of deaths associated with
a neurological condition as the underlying cause,
the contributory cause, or both. PD was the most
commonly recorded underlying neurological cause of
death (14% of deaths associated with a neurological
condition). Remarkably, falls (6%) and pneumonia
(3%) were among the 10 most common underlying
causes of deaths associated with a neurological con-
dition, while Alzheimer’s disease, vascular dementia
and unspecified dementia were each recorded on only
1% of death certificates. Falls and pneumonia may
have occurred as a complication of parkinsonism
or dementia (including dementia with Lewy bod-
ies) in some patients, which implies that the report
may have underestimated how often these diseases
are the underlying cause of death. Indeed, falls and
fall-related injuries are very common in Parkinson
patients, and hip fractures in this population are asso-
ciated with high mortality rates [4, 5]. Aspiration
pneumonia secondary to dysphagia is also a com-
mon cause of death for Parkinson patients [6]. On the
other hand, some misclassification of a diagnosis of
PD may have occurred, as a previous study showed
that almost one in six patients with a diagnosis of PD
in the population did not fulfil strict clinical criteria
for the disease [7].
Taken together, these data demonstrate that deaths
associated with PDRD are common in the population.
AGE AND PLACE OF DEATHS
Deaths associated with PDRD were the only group
of neurological conditions for which the mean age at
death was higher than the overall mean age at death in
the population (82 vs. 78 years, data reported for the
2012–2014 period). PD is not exclusively diagnosed
in the very elderly, [8] and the high age at death sug-
gests that PD patients live for long periods of time
with this condition. Considering the projected rise
in life expectancy globally, more resources will be
needed to take care of elderly patients with PD.
Care homes were the most common place of death
among patients with PDRD, occurring in 43% of
cases. Notably, healthcare professionals working in
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these institutions frequently lack Parkinson-specific
expertise [9]. Perhaps dedicated Parkinson nursing
homes or Parkinson-specific training programs could
help to reduce some preventable deaths. Aside from
care homes, 41% of deaths associated with PDRD
were recorded in hospitals, 14% occurred at home,
and 2% in other places. By comparison, 23% of
all-cause deaths and 18% of deaths associated with
neurological conditions occurred at home. These data
suggest that, despite recent improvements, [9, 10] the
end-of-life for PD patients is often unplanned and
occurring in hospitals or care homes. Although there
are undeniably instances when dying in a hospital is
more appropriate than dying at home, most patients
indicate a preference for dying at home [10]. Family
caregivers also typically indicate their own home as
the preferred place of care for their relatives towards
the end-of-life [11]. Furthermore, the vast majority
of hospital admissions of PD patients are unplanned,
resulting from either complications of the disease or
its treatments or comorbidities [12, 13].
Parkinson-specific training of professionals work-
ing in the community might prevent some of
these unscheduled admissions. For instance, care
delivery by physiotherapists with specific exper-
tise in Parkinson management was associated with
fewer hospital admissions due to fractures, other
orthopaedic injuries or pneumonia, as compared
to regular care by a generically trained therapist
[14]. Further gains may be made by introducing
intensive case management for community-dwelling
Parkinson patients, entailing a personalised, collab-
orative plan of care, not only for but also with
patients and their families. Also, closer collaboration
between university clinics and regional community
hospitals may improve delivery of optimal patient
care, with an emphasis on care delivered close
to the patient’s home whenever possible, but with
seamless access to more remote specialized care
whenever needed. Specific areas of collaboration may
include peer-to-peer support (e.g., university cen-
tres supporting community-based colleagues with
less expertise), diagnostics in university clinics for
unclear cases, shared education programs for patients
and professionals, and improved regional guideline
development.
TEMPORAL TRENDS
The number of all-cause deaths per year gradu-
ally declined between 2001 and 2006 and remained
relatively stable between 2007 and 2014. Compared
to 492,205 deaths in 2001, there were 464.556 in
2014, representing a 6% decline. By contrast, the
yearly number of deaths associated with a neuro-
logical condition increased steadily from 23,051 in
2001 to 31,925 in 2014, representing a 39% increase
over this relatively short time period. The number of
deaths associated with PDRD increased from 6,963 to
10,067 during the study period, indicating a marked
45% rise. There were even steeper relative rises
in mortality associated with neuromuscular diseases
(+83%), epilepsy (+70%), and traumatic brain and
spine injury (+64%). Ageing of the population did
not fully account for the observed rise in mortal-
ity associated with a neurological condition, since
age-standardised mortality for deaths associated with
a neurological condition only increased by 12%.
Age-standardised mortality of deaths associated with
PDRD rose by 10%.
The increase in mortality associated with PDRD
may be reflective of a rise in the incidence, a longer
survival after diagnosis, an increased awareness of
coding these conditions on death certificates in Eng-
land, or a combination thereof. Temporal trends in
the incidence of parkinsonism, including its most
common cause PD, have varied substantially across
populations around the world [15–18]. It is possi-
ble that differential temporal changes in exposure
to risk factors (e.g., exposure to airborne pollutants,
toxins such as pesticides, heavy metals or solvents)
have resulted in discrepant trends in the incidence
of parkinsonism across populations. Furthermore, we
consider the possibility that survival after diagnosis
among parkinsonism patients may have increased as a
result of improvements in multidisciplinary care dur-
ing the last decade [14, 19, 20]. Future studies are
warranted to elucidate to what extent such changes
may have affected the observations in the Public
Health England report.
Interestingly, age-standardised mortality of almost
every group of neurological conditions increased
throughout the study period. This suggests that an
improved awareness of neurological conditions or
a more complete registration of contributory causes
on death certificates by healthcare professionals over
time may have contributed to the observed rise in mor-
tality associated with PDRD. Unfortunately, it is not
clear whether the number of contributory conditions
listed on death certificates changed during the study
period. We also note that some individuals who were
diagnosed with dementia but not with PDRD may
have had an alpha-synucleinopathy, suggesting that
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the observed mortality rate associated with PDRD
reflects an underestimate of the mortality rate associ-
ated with alpha-synucleinopathies. Conversely, it is
possible that not all individuals with PDRD had an
alpha-synucleinopathy.
IMPLICATIONS FOR FUTURE
HEALTHCARE NEEDS
Health care planning should properly anticipate
a possible further rise in mortality associated with
PDRD. Efforts should particularly be focused on
providing resources for vulnerable elderly patients
with these disorders, avoiding unplanned hospital
admissions and out-of-home deaths as much as pos-
sible. Possible solutions include a community-based
network of specifically trained allied health thera-
pists, personal case managers for Parkinson patients,
dedicated Parkinson nursing homes, and improved
centralised support services from university clinics
to regional community hospitals aimed at facilitating
optimal wide-scale care delivery.
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